Weight Loss

Popular weight loss drugs could protect kidneys and heart

A major new study has shown that a group of drugs called GLP-1 receptor agonists offer strong protection for both the kidneys and the...

This new drug shows promise for treating obesity

Obesity is a major health problem all over the world. It increases the risk of many serious diseases, including heart problems and diabetes. Despite...

This therapy can boost weight loss in middle-aged women

A new study shows that using tirzepatide together with menopause hormone therapy can lead to greater weight loss in postmenopausal women who are overweight...

Study shows the real cause of obesity

A new study from Duke University challenges the popular belief that people are gaining weight because they are becoming less active. Researchers found that in...

New diabetes drug works faster for blood sugar and weight loss

A new study has found that a diabetes medicine called tirzepatide can help people lower their blood sugar and lose weight faster than other...

Can Ozempic quiet the urge to binge eat? What we know so far

Drugs like Ozempic and Mounjaro are becoming increasingly popular for treating obesity and type 2 diabetes. These medications belong to a group called GLP-1 agonists,...

Popular weight loss drug may increase vision loss risk

A new study from Mass Eye and Ear suggests that people taking semaglutide, a drug sold as Ozempic and Wegovy, may have a higher...

New drug could offer hope for treating obesity without diet or exercise

Obesity is a serious global health problem that raises the risk of heart disease, diabetes, and some types of cancer. Yet, there are still...

New obesity drug may slow breast cancer growth

A new study has found that a drug used for treating obesity and type 2 diabetes may also help slow the growth of breast...

Obesity-linked cancer deaths have tripled in the U.S. over 20 years

Cancer deaths linked to obesity have tripled in the United States over the last 20 years, according to new research presented at ENDO 2025,...